[Co-trimoxazole chemoprophylaxis in immunocompromised patients: analysis of the literature].
Gava
R
R
Carli
M
M
D000328:Adult; D000380:Agranulocytosis / Q000150:complications; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control*; D002648:Child; D004338:Drug Combinations / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D009369:Neoplasms / Q000150:complications; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014295:Trimethoprim / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000890:Anti-Infective Agents; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Chemioprofilassi con co-trimozzasolo in pazienti immunocompromessi: analisi della letteratura.